Verzenio Improves Overall Survival in Hormone Receptor-Positive, HER2-Negative, Advanced Stage Breast Cancer

At the European Society for Medical Oncology Congress 2022, Dr. Matthew Goetz presented interim overall survival results from the MONARCH 3 study showing that adding Verzenio to an aromatase inhibitor improves overall survival by 12.6 months for advanced-stage, hormone receptor-positive, HER2-negative breast cancer. Listen to the podcast to hear Dr. Goetz explain: how Verzenio works the aims of MONARCH 3 study the difference between progression-free and overall survival and why each is important Verzenio side effects what the results mean for people diagnosed with advanced-stage, hormone receptor-positive, HER2-negative breast cancer